http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Current Status of Cryotherapy for Prostate and Kidney Cancer
조석,강석호 대한비뇨의학회 2014 Investigative and Clinical Urology Vol.55 No.12
In terms of treating diseases, minimally invasive treatment has become a key elementin reducing perioperative complications. Among the various minimally invasive treatments,cryotherapy is often used in urology to treat various types of cancers, especiallyprostate cancer and renal cancer. In prostate cancer, the increased incidence of low-risk,localized prostate cancer has made minimally invasive treatment modalities an attractiveoption. Focal cryotherapy for localized unilateral disease offers the added benefitof minimal morbidities. In renal cancer, owing to the increasing utilization of cross-sectionalimaging, nearly 70% of newly detected renal masses are stage T1a, making themmore susceptible to minimally invasive nephron-sparing therapies including laparoscopicand robotic partial nephrectomy and ablative therapies. This article reviews thevarious outcomes of cryotherapy compared with other treatments and the possible usesof cryotherapy in surgery.
Gabapentin for the Treatment of Chronic Pelvic Pain Syndrome in Patients with High Pain Score
조석,In-Rae Cho 대한요로생식기감염학회 2019 Urogenital Tract Infection Vol.14 No.2
Purpose: The underlying pathogenic mechanisms of chronic pelvic pain syndrome (CPPS) are unclear. A growing body of evidence suggests that the urogenital pain of CPPS may be neuropathic in origin. The objective of this study was to determine if gabapentin can be an effective treatment for the symptoms of CPPS with severe pain.Materials and Methods: Thirty five males with CPPS (category IIIa 25, IIIb 10) and the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total pain score ≥9 in the previous six months were enrolled in this study between October 2010 and December 2011. The dosage of gabapentin was increased from 300 mg/d to 600 mg/d during the first four weeks. The primary outcome was evaluated as an improvement in the NIH-CPSI from the baseline to week eight.Results: This study examined 35 males with CPPS and a mean age of 54.2±9.8 years, mean disease duration of 34.2±27.7 months, and a mean prostate volume of 24.9±5.3 ml. The decrease in the total NIH-CPSI pain domain at four weeks was significant with no change observed after eight weeks. Between the category IIIa and IIIb CPPS patients, the change in the total pain domain was not significant.Conclusions: Gabapentin may be effective in some males with CPPS who have a high pain score. More gabapentin may be useless and possibly harmful if gabapentin does not decrease the pain at four weeks.